Address book

Contacts

Staff Structures

NICOLA FERRI

Back to the list

Position

Professore Ordinario

Structure

Dipartimento di Medicina - DIMED

Address

LARGO E. MENEGHETTI, 2 -PADOVA

Telephone

0497923236

E-mail

nicola.ferri@unipd.it

Dr. NICOLA FERRI

PERSONAL DATA
Date of birth: October 25, 1971
Place of birth: Mede Lomellina (PV), Italy
Nationality: Italian
Mailing address: Department of Pharmaceutical and Pharmacological Sciences
University of Padua
Largo Egidio Meneghetti 2
35131 Padua, Italy

EDUCATION
1990 Student in Pharmaceutical Chemistry and Technology, University of Milan, Italy
1996 Doctor in Pharmaceutical Chemistry and Technology, "Magna cum Laude", University of Milan, Italy
1998 Ph.D. in “Experimental Pharmacology” at the University of Milan, Italy
2002 Ph.D. in "Toxicology of Environment and Nutrition" at the University of Milan, Italy
2006 Master in “Pharmacy and Oncological Pharmacology” at the University of Milan, Italy

RESEARCH EXPERIENCE
2021- Full Professor in Pharmacology, Department of Medicine, University of Padua
2018- Associate Professor in Pharmacology, Department of Pharmaceutical Science, University of Padua
2015- 2018 Research Assistant Professor (RTDB), Department of Pharmaceutical Science, University of Padua
2014 - 2015 Research Assistant Professor (RTDA), Department of Biomolecular and Pharmacological Sciences, University of Milan
2003-2014 Post-Doctoral position at the University of Milan, Department of Pharmacological and Biomolecular Sciences, University of Milan
2004 "Visiting Scientist" (2 months) at the University of Washington (Seattle, USA) in the laboratory directed by Elaine Raines
1999-2003 "Senior Research Fellow" at the Department of Pathology, School of Medicine, University of Washington, Seattle, WA, USA in the Laboratory directed by Dr. Russell Ross and Prof. Elaine W. Raines
1999-2002 Doctoral Research in the laboratory directed by Prof. Remo Fumagalli, Institute of Pharmacological Sciences, University of Milan
1997-1999 Doctoral Research in the laboratory directed by Prof. Remo Fumagalli, Institute of Pharmacological Sciences, University of Milan

HONORS, SCOLARSHIPS, FELLOWSHIPS
1996-1998 Winner of a fellowship disposed by Pharmaceutical Company Tecnofarmaci S.C.p.A. Rome Italy.
1998-2002 Winner of a fellowship from Ph.D. school of Toxicology of Environment and Alimentation at the University of Milan
2003 Winner of scientific award "Giovanni Galli" at University of Milan, supported by Italian Society for the study of atherosclerosis (SISA).
2006 "Young Investigator Poster Award, Honorable Mention" at the XIV International Symposium of Atherosclerosis, Roma (Italia).
2006 Winner of the ward “Giovani Ricercatori” at University of Milan, supported by Italian Society for the study of atherosclerosis (SISA).
2007 Winner of Travel Grant SISA for the XXI National Congress of Italian Society for the study of atherosclerosis (SISA), Perugia (ITALY).
2008 Winner of the award “Giovani Ricercatori” supported by Italian Society for the study of atherosclerosis (SISA), Milan, ITALY.
2013 Winner of Travel Grant SISA for the XXVII National Congress of Italian Society for the study of atherosclerosis (SISA), Rome (ITALY).


RESEARCH INTEREST
Cardiovascular diseases; lipid metabolism; vascular biology

Notices

Office hours

  • at Largo E. Meneghetti 2 Padova
    Ricevimento su appuntamento

Teachings

Publications

1. Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012;220(2):381-386.
2. Adorni MP, Cipollari E, Favari E, et al. Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis. 2016;256:1-6.
3. Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A. Pharmacokinetics interactions of monoclonal antibodies. Pharmacological research. 2016;111:592-599.
4. Ferri N, Marchiano S, Tibolla G, et al. PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis. 2016;253:214-224.
5. Ruscica M, Ricci C, Macchi C, et al. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line. J Biol Chem. 2016;291(7):3508-3519.
6. Ruscica M, Ferri N, Fogacci F, et al. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. Journal of the American Heart Association. 2017;6(5).
7. Zimetti F, Caffarra P, Ronda N, et al. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2017;55(1):315-320.
8. Camera M, Rossetti L, Barbieri SS, et al. PCSK9 as a Positive Modulator of Platelet Activation. J Am Coll Cardiol. 2018;71(8):952-954.
9. Poggio P, Songia P, Cavallotti L, et al. PCSK9 Involvement in Aortic Valve Calcification. J Am Coll Cardiol. 2018;72(24):3225-3227.
10. Ricci C, Ruscica M, Camera M, et al. PCSK9 induces a pro-inflammatory response in macrophages. Scientific reports. 2018;8(1):2267.
11. Ferri N, Ruscica M, Coggi D, et al. Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study. Atherosclerosis. 2020;309:39-46.
12. Ruscica M, Corsini A, Ferri N, Banach M, Sirtori CR. Clinical approach to the inflammatory etiology of cardiovascular diseases. Pharmacological research. 2020;159:104916.
13. Ferri N, Ruscica M, Lupo MG, Vicenzi M, Sirtori CR, Corsini A. Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9. Pharmacological research. 2022;184:106439.
14. Lupo MG, Bressan A, Donato M, et al. PCSK9 promotes arterial medial calcification. Atherosclerosis. 2022;346:86-97.